Next, we assessed whether alisertib was capable to disrupt the interaction between c-Myc and Aurora kinase A. To this purpose, SF188 GBM cells were treated with increasing dosages of alisertib, followed by c-Myc immunoprecipitation. Here, MYC is linked to glioblastoma.